Cargando...
Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care
BACKGROUND: Rivaroxaban, a fixed-dose oral direct factor Xa inhibitor, does not require continuous monitoring and thus reduces the hospital stay and economic burden in low-risk pulmonary embolism (LRPE) patients. STUDY QUESTION: What is the effectiveness of rivaroxaban versus the standard of care (S...
Gardado en:
| Publicado en: | J Health Econ Outcomes Res |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Columbia Data Analytics, LLC
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7299482/ https://ncbi.nlm.nih.gov/pubmed/32685588 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.36469/9936 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|